The GLP-1 app women on Ozempic, Wegovy, Mounjaro and Zepbound have been waiting for.
Steady is the only iPhone app built specifically around how GLP-1 medications work, for women, with cycle awareness baked in.
There are hundreds of weight-loss apps. Most of them were designed before GLP-1 medications became mainstream. They count calories. They suggest deficits. They congratulate the scale. They have no idea why protein matters more now, why muscle is at risk, or why your symptoms follow your cycle.
Steady is the small, sharp tool that does the GLP-1 job. Each one of the eight approved medications, Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, Rybelsus, and a placeholder for women who are still deciding, has its own titration schedule built in. The home screen shows you what the medication is supposed to be doing this week. The logging screen knows the symptoms that matter on a GLP-1, not a generic list of headaches.
Free to start. Subscription unlocks the AI coach, the full history, and the cycle-aware features. Cancel any time through Apple, one tap.
Built around how this medication actually works.
Eight medications, all titration schedules
Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, Rybelsus and undecided.
Six injection sites, rotated for you
Abdomen, thigh, upper arm, left and right. Six weeks per site to heal. Suggested next site every week.
An AI coach that reads your day
Powered by a clinical-context engine. Knows your dose, your symptoms, your cycle phase before it answers.
Built for the Apple ecosystem
iCloud-aware. HealthKit-ready. Native iOS performance, no compromise.
What the studies actually say.
Evidence-based summaries of the papers that informed every part of this page. Each article cites its sources.
Mounjaro vs Wegovy: how to think about the choice
Tirzepatide loses more weight on average. Semaglutide has more years of safety data. The right answer is rarely about averages, here's the framework your prescriber is probably…
Tirzepatide vs Semaglutide: A Calm Decision Guide for Women
Tirzepatide vs semaglutide, explained for women on GLP-1: how each molecule works, the head-to-head evidence, side effects, and the real decision criteria.
The month-four plateau on a GLP-1: why it happens, and what to do about it
The first eight weeks fly. Then the scale stops. This is not the drug failing, it is your body doing what bodies do. Here's the maths, and the three levers that move it again.
Why Weight Comes Back After Ozempic: The Set Point, Explained
Why weight comes back after Ozempic is biology, not failure. How the set point, hormone rebound, and lost muscle work, and the one lever you control.
Mood, anxiety, and GLP-1s: what the data actually shows
There were reports. There were FDA reviews. There were headlines. Here is a careful look at what the suicidality and mental-health data on GLP-1s really says, and what to do if…
GLP-1, the Brain, Dementia and Mood: The Honest Picture
What we know about GLP-1, brain, dementia and mood: lower dementia and addiction risk in observational data, but no benefit in early Alzheimer disease.
How to make your GLP-1 doctor's visit actually useful
Ten minutes goes fast. Most women leave the appointment without having asked the questions that would have changed the next three months. Here is the worksheet to walk in with.
How to rotate your GLP-1 injection sites, and why it matters more than you think
Always the same spot. Always the same time. Always the same low-grade lump under the skin. Here is the rotation pattern that prevents lipohypertrophy, and the technique notes most…
Insulin resistance on a GLP-1: the metabolic marker that often changes first
The scale is the slowest line on the chart. Insulin resistance often improves before the weight changes meaningfully, sometimes within weeks. Here is what that means, and what to…
Compounded semaglutide and tirzepatide: what is, and isn't, the same
When supply ran short, compounded versions of GLP-1s flooded the market. With the shortage over, the FDA is winding them down. Here is what the difference actually is, and why…